TY - JOUR
T1 - Janus Kinase Inhibitors and Risk of Venous Thromboembolism
T2 - A Systematic Review and Meta-analysis
AU - Bilal, Jawad
AU - Riaz, Irbaz Bin
AU - Naqvi, Syed Arsalan Ahmed
AU - Bhattacharjee, Sandipan
AU - Obert, Michelle R.
AU - Sadiq, Maryam
AU - Abd El Aziz, Mohamed A.
AU - Nooman, Yahya
AU - Prokop, Lary J.
AU - Ge, Long
AU - Murad, Mohammad H.
AU - Bryce, Alan H.
AU - McBane, Robert D.
AU - Kwoh, C. Kent
N1 - Publisher Copyright:
© 2021 Mayo Foundation for Medical Education and Research
PY - 2021/7
Y1 - 2021/7
N2 - Objective: To assess the risk of venous thromboembolism (VTE) in patients treated with Janus kinase (JAK) inhibitors in clinical trials. Patients and Methods: We performed a literature search of Ovid MEDLINE and ePub Ahead of Print, In-Process & Other Non-Indexed Citations, and Daily; Ovid EMBASE; Ovid Cochrane Central Register of Controlled Trials; Ovid Cochrane Database of Systematic Reviews; and Scopus, from inception to December 4, 2019, for randomized, placebo-controlled trials with JAK inhibitors as an intervention and reported adverse events. Odds ratio with 95% CI was calculated to estimate the VTE risk using a random effects model. Two independent reviewers screened and extracted data. The GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach was used to assess certainty in estimated VTE risk. Results: We included 29 trials (13,910 patients). No statistically significant association was found between use of JAK inhibitors and risk of VTE (odds ratio, 0.91; 95% CI, 0.57 to 1.47; P=.70; I2=0; low certainty because of serious imprecision). Results using Bayesian analysis were consistent with those of the primary analysis. Results of stratified and meta-regression analyses suggested no interaction by dose of drug, indication for treatment, or length of follow-up. Conclusion: We found insufficient evidence to support an increased risk of JAK inhibitor–associated VTE based on currently available data.
AB - Objective: To assess the risk of venous thromboembolism (VTE) in patients treated with Janus kinase (JAK) inhibitors in clinical trials. Patients and Methods: We performed a literature search of Ovid MEDLINE and ePub Ahead of Print, In-Process & Other Non-Indexed Citations, and Daily; Ovid EMBASE; Ovid Cochrane Central Register of Controlled Trials; Ovid Cochrane Database of Systematic Reviews; and Scopus, from inception to December 4, 2019, for randomized, placebo-controlled trials with JAK inhibitors as an intervention and reported adverse events. Odds ratio with 95% CI was calculated to estimate the VTE risk using a random effects model. Two independent reviewers screened and extracted data. The GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach was used to assess certainty in estimated VTE risk. Results: We included 29 trials (13,910 patients). No statistically significant association was found between use of JAK inhibitors and risk of VTE (odds ratio, 0.91; 95% CI, 0.57 to 1.47; P=.70; I2=0; low certainty because of serious imprecision). Results using Bayesian analysis were consistent with those of the primary analysis. Results of stratified and meta-regression analyses suggested no interaction by dose of drug, indication for treatment, or length of follow-up. Conclusion: We found insufficient evidence to support an increased risk of JAK inhibitor–associated VTE based on currently available data.
UR - https://www.scopus.com/pages/publications/85103979271
UR - https://www.scopus.com/pages/publications/85103979271#tab=citedBy
U2 - 10.1016/j.mayocp.2020.12.035
DO - 10.1016/j.mayocp.2020.12.035
M3 - Article
C2 - 33840525
AN - SCOPUS:85103979271
SN - 0025-6196
VL - 96
SP - 1861
EP - 1873
JO - Mayo Clinic Proceedings
JF - Mayo Clinic Proceedings
IS - 7
ER -